Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest major cancers, with a five year survival rate of less than 8%. With current therapies only giving rise to modest life extension, new approaches are desperately needed. Even though targeting polyamine metabolism is a proven anticancer strategy, there are no reports, which thoroughly survey the literature describing the role of polyamine biosynthesis and transport in PDAC. This review seeks to fill this void by describing what is currently known about polyamine metabolism in PDAC and identifies new targets and opportunities to treat this disease. Due to the pleiotropic effects that polyamines play in cells, this review covers diverse areas ranging from polyamine metabolism (biosynthesis, catabolism and transport), as well as the potential role of polyamines in desmoplasia, autophagy and immune privilege. Understanding these diverse roles provides the opportunity to design new therapies to treat this deadly cancer via polyamine depletion.
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest major cancers, with a five year survival rate of <8%. Few treatments are available beyond radical surgery and chemotherapeutic agents. 1 Due to the lack of early diagnostic tools, 80% of patients present with advanced disease at the time of diagnosis. 2 The current standard of care includes gemcitabine (GEM, a DNA synthesis inhibitor), Abraxane (protein particles which deliver paclitaxel) and FOLFIRINOX (a combination therapy with the drugs oxaliplatin, irinotecan, 5-fluorouracil and leucovorin). [2] [3] [4] Only modest gains in survival time (6 months) are observed, regardless of whether GEM is used alone or in combination with an epidermal growth factor receptor inhibitor. 2 FOLFIRINOX was shown to provide an additional five-month survival increase over GEM (11 months total). 2, 4 Targeting stromal components is an area of intense interest and Abraxane has been shown to target SPARC (secreted protein acidic and rich in cysteine). SPARC is a glycoprotein often secreted by PDAC cells into the extracellular matrix and has been shown to increase invasive capacity and lead to poor prognosis. 5 Beyond
Abraxane, however, few therapies address the protective role of the tumor stroma in tumor survival 6 and novel diagnostics and therapies are desperately needed. This report provides an overview of polyamine metabolism in pancreatic cancers. Prior research has suggested that pancreatic cancers are addicted to polyamine growth factors and that inhibition of polyamine metabolism may constitute a viable treatment for these cancers. 7 Polyamines play key roles in processes associated with tumor growth, spread and survival including translation, transcription, chromatin remodeling, autophagy, metastasis, tumorigenesis, immune privilege and formation of eIF5A. [8] [9] [10] [11] Because the native polyamines (putrescine, spermidine and spermine, Fig. 1 ) influence many biological processes, this approach provides the opportunity to perform "polypharmacy" on cancers, that is, the simultaneous targeting of several tumor-promoting pathways through intracellular polyamine depletion.
The diverse literature describing polyamines and their pleiotropic effects on cancer cells is summarized with a particular focus on their contributions to the different processes driving pancreatic cancer progression. Specifically, this report focuses on the most common type of pancreatic cancer: PDAC, which accounts for 95% of primary pancreatic malignancies.
cancers are known to increase intracellular polyamine levels, which drive tumor growth. 8, 14, 15 At physiological pH, native polyamines exist as polycations allowing them to interact with anionic biomolecules like RNA, DNA and proteins, causing pleiotropic cellular effects. 8 Many human cancer types have elevated polyamine levels relative to normal cells. This is very significant in pancreatic cancers. 16 Indeed, even normal pancreas spermidine levels are the highest of any mammalian tissue. 17, 18 Polyamine homeostasis is tightly regulated and is maintained by a balance between polyamine biosynthesis, catabolism and transport. These three processes will be briefly described to introduce the specific proteins involved in polyamine metabolism with their known relationships.
Polyamine Biosynthesis
As shown in Figure 2 , polyamine biosynthesis relies upon Lornithine (L-Orn) supply. Arginine is converted to ornithine via the action of arginase (ARG1). Interestingly, increased serum ARG1 levels have been observed in patients with pancreatic cancer, where immune suppression by myeloid-derived suppressor cells (MDSCs) is thought to occur via enhanced arginine catabolism. 19 This also leads to increased L-Orn levels, required for the synthesis of the native polyamines (Fig. 1) . Polyamine biosynthesis involves the conversion of L-Orn to putrescine via ornithine decarboxylase (ODC), followed by the formation of spermidine via spermidine synthase (SRM) and S-adenosylmethioninamine (decarboxylated S-adenosyl methionine, formed by S-adenosylmethionine decarboxylase or AMD1). The S-adenosylmethioninamine provides the required aminopropyl fragment needed to produce spermidine from putrescine. In a similar manner, spermine is then generated from spermidine via spermine synthase (SMS) and AMD1. The tight control on polyamine biosynthesis is exerted in part by the rate-limiting enzyme ODC, which is negatively regulated by interaction with antizyme 1 (OAZ1), which targets it for destruction in the proteasome. 20 OAZ1 itself is negatively regulated by antizyme inhibitor 1 (AZIN1). 21 Increased AZIN1 levels inhibit OAZ1, increasing ODC putrescine biosynthesis. Interestingly, OAZ1 also negative regulates polyamine import by a yet unknown mechanism. [22] [23] [24] [25] [26] Thus, OAZ1 regulates both polyamine biosynthesis and transport to maintain homeostasis. Polyamine homeostasis is also regulated via catabolic processes.
Polyamine Catabolism
Polyamine catabolism typically involves N-acetylation of the aminopropyl end of spermine by spermine/spermidine acetyl transferase (SAT1) to form N 1 -acetylspermine (NAc-Spm, Fig. 1 ) and N 1 ,N 12 -diacetylspermine (diAc-Spm). 27 SAT1 also converts spermidine to N 1 -acetylspermidine (N1Ac-Spd). These N-acetylated polyamine metabolites are substrates for polyamine oxidase (PAO), which recognizes the N-acetylated aminopropyl tail, cleaves it and back-converts the substrate to the respective lower polyamine, for example, spermidine or putrescine (Fig. 2) . 27 Acetylated polyamines are also substrates for export via the diamine transporter (DAX), a heterodimer of the solute carrier SLC3A2 and the arginine transport y 1 LAT. 28, 29 Since SAT1 can coimmunoprecipitate with SLC3A2, a physical coupling of polyamine breakdown and transport could exist. 28 In sum, all three processes (polyamine biosynthesis, breakdown and transport) are interconnected to maintain homeostasis. 27 This polyamine homeostatic network can also be modulated by extracellular signals. For example, SAT1 is a specific binding partner with the a9 integrin cytoplasmic domain and is required for a9b1-mediated cell migration. 30, 31 Indeed, localized SAT1 N-acetylation of spermidine and spermine opens the Kir4.2 potassium channel and increases cell migration. 30, 31 Collectively, these observations suggest a physical coupling of integrin outside-in signaling and polyamine catabolism. This is an example of polyamine metabolism regulating an inward rectifier channel to affect cell migration. 31 Moreover, small molecule inducers of the catabolic SAT1 gene caused profound depletion of pancreatic polyamines and acute pancreatitis suggesting that one needs to maintain sufficient levels of the higher polyamines to maintain pancreatic integrity. 32 In this regard, the location and activity of polyamine catabolic enzymes can dramatically affect cell migration.
Given the connection between polyamines and cell migration, a role has been suggested for polyamines in tumor spread 9 and a prior study suggested that polyamines do indeed play essential roles in tumor metastases. 33 For example, murine experiments using Lewis Lung (3LL) tumors treated with difluoromethylornithine (DFMO, an inhibitor of ODC), showed a 40-50% inhibition of growth of the primary tumor and an 80% reduction in pulmonary metastases. 33 This beneficial effect of DFMO was reversed by the simultaneous administration of putrescine suggesting that polyamines play an important role in metastasis. 33 Similar results with DFMO in reducing breast cancer metastases have also been reported. 34 Along these lines, an interesting connection between metastasis, spermidine catabolism and the polyaminehypusine circuit has been suggested. 35 A unique aminoacid residue (hypusine) is created via a post-translational modification of the eukaryotic initiation factor 5 A-1 (eIF-5A1) precursor protein via deoxyhypusine synthase (DHPS) and spermidine catabolization. Hypusine formation (i.e., hypusinylation) involves the attachment of an aminobutyl fragment from spermidine to a specific N E -lysine residue of the eIF5A1 precursor via DHPS. Functional eIF5A-1 protein is then made via deoxyhypusine hydroxylase (DOHH), which inserts a hydroxyl group in a regio-and stereospecific manner on the appended aminobutyl sidechain. In terms of PDAC, knockdown of eIF5A1 was shown to reduce PDAC cell migration and metastasis to the liver. 36 Since eIF5A1 incorporates a physical fragment of the spermidine molecule itself, this is an excellent example of how polyamines can indirectly influence PDAC cell metastasis 36 and cell growth. 37 The connection between polyamines and the related eIF5A2 protein provides another example of how polyamines influence metastatic potential by promoting the epithelialmesenchymal transition (EMT). For example, overexpression of the spermidine-derived eIF5A2 promoted EMT and has been shown to lead to metastasis in several cancer types. 35 In contrast, inhibition of hypusinylation by a small molecule inhibitor of DHPS or depletion of eIF5A2 by siRNA provokes a mesenchymal to epithelial transition as evidenced by increased epithelial markers (E-cadherin and b-catenin) and decreased mesenchymal markers (vimentin and fibronectin). 35 In short, the post-translational contribution of polyamines to the generation of fully-functional eIF5A proteins provides cancer cells with the ability to undergo EMT and metastasize to distal sites.
An alternative catabolic pathway exists, where spermine can be directly converted to spermidine via spermine oxidase (SMOX). Both PAO and SMOX produce hydrogen peroxide, creating reactive oxygen species (ROS) and can cause oxidative stress to the cell. 38, 39 Oxidative stress is increased in pancreatic cancers 40 and plays an important role in PDAC including the acquisition of invasive and aggressive phenotypes and has been recently reviewed as a therapeutic target in PDAC. 41, 42 Polyamine Transport
Polyamine transport in humans is not well described beyond the diamine exporter DAX (i.e., SLC3A2) and can involve the direct export of native polyamines as well as N-acetylated polyamines (for a review, see Poulin et al. 43 ). There are examples of transporters that import polyamines directly into the cytosol followed by sequestration into polyaminesequestering vesicles 43 as well as examples of polyamine cellsurface capture by heparan sulfate proteoglycans (HSPGs) and uptake via endocytosis. 43 Specific transport proteins have been linked to polyamine transport including the plasma membrane transporter (SLC12A8) 44 and caveolin-1 (CAV1) dependent endocytosis.
A recent report described how developing PDAC tumors may select for alterations in noncoding regulatory elements of specific genes to control specific pathways. 45 Interestingly, low mRNA expression of the polyamine transporter SLC12A8 was associated with both decreased disease free survival and decreased overall survival in PDAC patients. 45 Two specific A-to-C mutations in an important regulatory site on chromosome 3 altered the binding site of the IRF1 (and/or PRDM1) transcription factor(s). 45 Interestingly, this binding site lies in the intron of one isoform and the promoter region of an alternative isoform of SLC12A8. 45 It is possible that developing PDAC tumors regulate this transport protein in order to establish directional polyamine exchange with stromal cells.
The CAV1 endocytotic mechanism involves initial capture of spermine by HSPGs anchored to the cell membrane via glypican-1 (GPC1), followed by CAV1-mediated endocytosis. Nitric oxide (NO) generated by nitric oxide synthase 2 then cleaves the polyamine/heparan sulfate complex and the polyamine escapes the endosome by an unknown mechanism.
46-49 CAV1 negatively regulates polyamine transport, whereas GPC1 enhances polyamine transport. Therefore, PDAC cells with high GPC1 and low CAV1 are likely to have high polyamine uptake via this pathway.
The HSPG glypican-1 is indeed strongly expressed in both pancreatic carcinoma cells and the adjacent fibroblasts. 50 In contrast, GPC-1 expression was found to be low in both normal pancreas and chronic pancreatitis. 50 Moreover, stable transfection of a GPC1 antisense construct decreased tumorigenicity in PANC-1 pancreatic cancer cells 51 indicating a role for GPC1 in tumor progression. Consistent with this, overexpression of the arylsulfatase enzyme (Hsulf-1) in PANC-1 pancreatic cancer cells decreased HSPG sulfation, removing the key sulfate anion used in polyamine capture and resulted in reduced cell growth. 52, 53 A recent survey of human PDAC cell lines also suggested a role for the P 5B type ATPase ATP13A3 in polyamine transport. [54] [55] [56] PDAC cell lines with high ATP13A3 expression had high V max for spermidine import, and ATP13A3-specific siRNA significantly reduced rescue from the ODC inhibitor, DFMO, via the import of exogenous spermidine. 54 
Oncogenes and Polyamine Metabolism
Given that polyamines are critical for cell proliferation, it is no surprise that many oncogenes drive polyamine metabolism via upstream signaling pathways.
For example, in colorectal cancers oncogenic KRAS has been shown to induce ODC, and phosphorylate CAV1 at Tyr-14, which increases polyamine transport via a caveolindependent endocytosis pathway. 15 Using the RAF-MEK-ERK-c-myc-ODC signaling pathway, mutant KRAS in PDAC can drive enhanced polyamine metabolic flux and increase tumor proliferation. In support of this idea, Mohammed et al. have shown that polyamine synthesis and ODC modulation starts in early pancreatic precursor lesions, and increases during tumor progression in K-ras LSL.G12D/1 ; p48
Cre/1 (KC) mice. 12 Mohammed et al. also showed that DFMO treatment can diminish tumor initiation, suggesting that polyamines are critical for intermediate tumor development. 12 Beyond KRAS mutations, the mutation or loss of key tumor suppressor genes like CDKN2a (a.k.a. p16), p53 and SMAD4 are also common in PDAC. 57 Their loss increases cell cycle rates (thru CDKN2a loss) and increases resistance to apoptosis and KRAS G12D induced senescence (via p53 loss). 58 These genes also have connections to polyamine metabolism. For example, methylthioadenosine phosphorylase (MTAP) is a key enzyme involved in the catabolism of methylthioadenosine, which is a byproduct of polyamine metabolism. 59 Interestingly, the MTAP locus is 100 Kb distal to that of CDKN2a and loss of MTAP was originally thought to be a bystander effect associated with loss at that locus. However, subsequent studies indicated that MTAP is a tumor suppressor gene in itself and that loss of MTAP is common in PDAC and is associated with increased polyamine biosynthesis via upregulated ODC. 59 DFMO was shown to induce p53 in pancreatic tissues. 12 Experiments in intestinal epithelial cells demonstrated that depletion of intracellular polyamines by DFMO increased the basal level of SMAD4 proteins, induced their nuclear translocation and stimulated Smad-sequence specific DNA binding activity. 60 Interestingly, in a promoter wide analysis of SMAD4 binding sites in epithelial cells, SMOX was noted as a gene near the SMAD4 binding sites upregulated by transforming growth factor-beta (TGF-b) suggesting a potential connection between SMAD4 and spermine oxidase. 61 However, this dependency has yet to be confirmed via direct experiments. 61 In support of polyamine-mediated pancreatic tumor progression, MYC, which is downstream of KRAS, directly upregulates polyamine biosynthesis by ODC transcription activation. 8, 14 Specifically, MYC dimerizes with its partner protein MAX, and the dimer binds to E-box motifs (CACGTG) in the ODC promoter. 8 ODC increases intracellular putrescine levels and facilitates the biosynthesis of the higher polyamines (Fig. 2) . The fact that ODC signaling increases as PDAC develops and ODC activity is sufficient for tumor promotion in other cancers are both consistent with polyamines playing a role in PDAC growth. 62 Indeed, MYC levels were shown to correlate strongly with elevated polyamine levels and spermidine import V max in a series of PDAC cell lines. 8, 54 MYC upregulation, therefore, increases both polyamine biosynthesis 63 and import. 54 Lastly, a novel feedback mechanism has been proposed in other systems, where polyamines regulate MYC translation through Chk2-dependent Hur phosphorylation. 64 Therefore, Myc gene family driven tumors are likely "addicted" to polyamines and may be especially sensitive to therapies targeting polyamine metabolism.
PDAC tumor heterogeneity suggests that therapies should inhibit not only KRAS and its immediate downstream targets like RAF, MEK and ERK, but also common pathways required for tumor survival that are further downstream. Upstream signaling networks can bypass inhibition of a specific protein (e.g, c-RAF can compensate for BRAF inhibition in melanoma), whereas blockade of the actual effector molecules themselves (polyamines) may provide a general approach to tackle tumor escape by targeting its metabolic dependency. Indeed, shared metabolic traits like polyamine production and transport are frequently maintained between tumors, presenting a way to therapeutically address even tumors with high genetic complexity like PDAC. These hypotheses provided further impetus for investigation of polyamine metabolism in PDAC.
The pleiotropic effects of polyamines also likely contribute to several of the observed phenotypes associated with PDAC, including desmoplasia and immune privilege.
PDAC Stroma, Polyamines and Desmoplasia
One hallmark of PDAC tumors is their dense desmoplasia. Indeed, the PDAC stroma is complex and contains an abundance of extracellular matrix components. 65 Many cell types are present including fibroblasts, pancreatic stellate cells and immune and vascular cells. Each of these contribute to tumor survival and spread. 2 Treatment of PDAC is complicated by the poor perfusion of drugs into the tumor due to the extensive desmoplasia.
2 Direct targeting of the stroma using a Smoothened (SMO) small molecule inhibitor (IPI-926) increased survival in a genetically engineered mouse model of PDAC, 66 but clinical trials pursuing this approach were stopped due to poor performance. 6 Subsequent studies demonstrated in PDAC that certain cells within the stroma may actually restrain tumor progression by limiting metastasis. 67, 68 Desmoplasia consists mainly of extracellular matrix molecules such as collagens I, IV and VI along with fibroblasts, endothelial cells, immune cells and neurons. 58, 69 Enzymatically active transglutaminase 2 (TGM2) has been shown to be secreted into the PDAC stroma. TGM2 cross-links collagen and stimulates myofibroblast proliferation, which in turn activate the Yes-associated protein and the transcriptional coactivator with PDZ binding motif (TAZ) to promote cancer cell proliferation. 69, 70 Interestingly, TGM2 can use polyamines as substrates and covalently attach these to the Ç-glutamyl group of other proteins. Folk et al. suggested that polyamines (especially spermidine) may be physical components of the crosslinked extracellular matrix itself, providing an initial amine scaffold for crosslinking via TGM2. 71 Therefore, secreted extracellular polyamines in the tumor microenvironment may contribute to the extensive desmoplasia observed in PDAC by providing tethered amine functional groups for cross linking.
Although desmoplasia reduces the penetrance of chemotherapeutic agents, it also confines the tumor and disrupts its vascularization. This confinement creates hypoxia, forcing the tumor cells to undergo metabolic changes for survival. 58 A significant number of PDAC tumors are hypoxic, and shunt glucose to anaerobic glycolysis, which is much less efficient in ATP generation than oxidative phosphorylation. 58 This metabolic shift facilitates the shunting of glycolytic intermediates towards the generation of the macromolecules needed for cell proliferation (e.g., nucleic acid biosynthesis). 72 Stabilization of hypoxia-induced-factor-1a (HIF1A) and increased expression of glucose transporters and glycolytic enzymes help support this altered metabolism. 58 Interestingly, hypoxia has also been shown to induce polyamine transport and ODC as well as CAV1-mediated endocytosis, suggesting a strong connection between hypoxia, polyamine biosynthesis and uptake. [73] [74] [75] Interestingly, high HIF1A expression in PDAC patients was a strong predictor of poor clinical outcome. 76 
Polyamines, Autophagy and Immune Cells
Pancreatic cancer immunotherapy has recently received wide attention (for a recent review see Kunk et al.) 77 Many cell types were noted to play important contributions to tumor stage and survival. These include immune effector cell types (like natural killer (NK) cells, CD4 77 The activated T-cell response is critical for positive patient outcomes and the immune response is regulated, in part, by the programmed death protein-1 (PD-1) and the programmed death-ligand 1 (PD-L1). PD-1 is a cell surface receptor on T-cells and pro-B cells and acts as an immune checkpoint. Once bound to its ligand (PD-L1), PD-1 promotes apoptosis in antigen-specific T-cells and reduces apoptosis in T-regs. 78 Thus, high PD-L1 presentation by the tumor leads to a lowered immune response. As a result, patients with PD-L1 positive tumors typically have significantly worse outcomes than those with PD-L1 negative tumors. 79 Likewise, cytotoxic T-lymphocyte associated protein-4 (CTLA-4) is an inhibitory protein found on T-cells, which induces apoptosis and prevents T-cell overstimulation. CTLA-4 is overexpressed in pancreatic cancer cells and its expression correlated negatively with patient survival after post-surgical resection. 77 Unfortunately, T-cell immunotherapy has yet to produce significant advances in PDAC treatment, and neither anti-CTLA-4 nor anti-PD-L1 monoclonal antibodies have shown tumor-shrinking activity in humans or mice with PDAC. 80 Clearly, a better understanding of the immune-modifying small molecules in the PDAC microenvironment is needed.
Perhaps the most exciting features of polyamines are their documented roles in suppressing the immune response. In this regard, PDAC tumors, which secrete polyamines into their tumor microenvironment, can create a polyamine-rich zone of immune privilege.
Early investigations showed that polyamine deprivation prevents tumor-induced immune suppression. 81 More recent data shows that polyamines themselves can act as immune modulators. For example, the tetra-amine spermine, can downregulate the pro-inflammatory cytokine response of lipopolysaccharide (LPS)-stimulated macrophages. Indeed, a significant number of genes involved in macrophage IL-4 stimulation can be regulated by polyamines. 82 Spermine also suppresses macrophage cytokine synthesis through a specific post-transcriptional mechanism. 83 In contrast, spermidine was a relatively poor inhibitor of monocyte cytokine synthesis, and putrescine was generally inactive in this regard (Fig. 1) .
Polyamine immune modulation is best exemplified by macrophages, which secrete a spermine-binding protein, fetuin, which captures extracellular spermine, facilitates import of spermine into macrophages, and decreases macrophage immune response. 83, 84 Fetuin is also required for spermine suppression of tumor necrosis factor synthesis in LPSstimulated human monocytes. 83 Since spermine is released from dying or damaged cells at inflammatory sites, its extracellular concentration provides a local indicator of the degree of tissue injury and helps regulate macrophage immune response. This tempering of the macrophage inflammatory response is critical to protect the host from excessive inflammation.
Polyamines also affect peripheral blood mononuclear cell adhesion and decrease the cytotoxicity of killer cells, especially lymphocyte-activated killer cells.
9,85-87 Specifically, spermine decreases lymphocyte LFA-1 (CD11a/CD18) integrin expression. 86 Recently, spermidine was shown to play a role in T-cell immune memory by regulating autophagy. As shown in Figure 2 , spermidine can induce autophagy by inhibiting E1A-binding protein p300 (EP300), a known lysine acetyl transferase 88 and a suggested tumor suppressor gene. 89 Subsequent studies showed that an EP300 small molecule inhibitor, C646, could induce autophagy in both normal and enucleated cells, revealing the capacity of EP300 to repress autophagy by cytoplasmic effects. 88 In addition, spermidine was shown to inhibit EP300 acetylation of histone H3 and data was presented, which suggested that spermidine may be a competitive inhibitor of EP300. 88 This latter observation could explain why N 1 -acetylspermidine, the product of the spermidine and the acetyltransferase EP300 reaction, is detected in pancreatic cancer tissue, but not in normal pancreas. 16 Due to the high intracellular spermidine levels, spermidine likely acts as a sacrificial acetylation substrate and diverts acetyl units away from the normal EP300/histone modification to form N 1 -acetylspermidine. Since pancreatic cancers require autophagy for tumor growth, 90,91 the spermidine "addiction" of PDAC provides high intracellular spermidine pools to inhibit EP300 and facilitate the autophagic processes needed for tumor survival. Indeed, autophagy has been suggested to be the principal way that PDACs cope with the high metabolic flux, ROS and DNA damage associated with their growth (Fig. 3) . 90 In studies with Atg7-deleted T-cells, autophagy was shown to be nonessential for effector CD8
1 T-cell response, but required for the formation of memory CD8
1 T-cells. 92 Since spermidine induces autophagy, 88, 93, 94 T-cell spermidine pools may also support long term immune response via improved T-cell memory.
Neutrophils are the first responders of the innate immune system and initiate host immune defense. Spermine has been shown to inhibit neutrophil NADPH oxidase activation, suppressing superoxide generation, lowering their ability to mount an immune response. 95 Polyamines are also associated with mast cell secretory granules ("secretory lysosomes"), and spermidine is released along with histamine upon mast cell degranulation. 96 Isolated mast cell secretory granules contain both spermidine and spermine. 96 Polyamine depletion by DFMO led to changes in mast cell granule morphology and a significant decrease in the intracellular histamine and serotonin levels by a yet unknown mechanism. These observations suggest that polyamines play a role in mast cell granule homeostasis. 96 Dendritic cells play critical roles in directing host immune response and eliciting an antigen-specific host defense. 97 A recent report on a dendritic cell vaccine for pancreatic cancer suggested improved patient outcome. 98 While the effect of spermine on dendritic cells in PDAC is unknown, a significant inverse correlation between spermine concentration and the percentage of dendritic cells expressing IL-12 has been observed in breast cancers. 99 Spermine also impaired the function of monocyte-derived dendritic cells and dendritic cells generated in the presence of spermine had reduced capacity for antigen capture and impaired T-cell Figure 3 . Autophagy is required for PDAC development. As PDAC develops, metabolic demands, ROS and DNA damage all increase. These changes must be addressed to avoid cytotoxicity and are offset, in part, by induction of autophagy. In this regard, autophagy especially helps Pan-IN3 and PDAC lesions progress forward despite significantly increased cell stress. allostimulatory capacity. 99 Thus, spermine can reduce the ability of dendritic cells to mount an immune response.
In summary, the literature suggests that although spermidine and spermine both affect the immune response, spermine is a more potent immune modulator, while spermidine is a proven autophagy inducer.
Polyamine Transport as a Future Target
Given the diverse roles of polyamines in PDAC, there is increasing interest in developing therapies, which target polyamine metabolism. Ideally, this targeting should inhibit the ability of PDAC cells to use these compounds for tumor advantage. Since polyamines can be both biosynthesized and imported into cancer cells, a combination therapy of a polyamine biosynthesis inhibitor (e.g., DFMO) and a polyamine transport inhibitor (PTI) is required for efficient, sustained intracellular polyamine depletion. Polyamine depletion is expected to have dramatic consequences for the tumor, stroma and the overall immune response. 10, 11 A combination therapy of both biosynthesis and transport inhibitors is needed because DFMO treated cells are readily rescued by uptake of exogenous polyamines. While inhibitors of polyamine biosynthesis like DFMO are well known, efficient inhibitors of polyamine transport are less established and can vary in design. [100] [101] [102] [103] [104] The diverse architectures and performance of polyamine-based PTIs have been recently reviewed in detail. 105 We note that other small molecules, which do not contain polyamines within their structure, can result in polyamine depletion when used in combination with DFMO. For example, in colon cancers the non-steroidal antiflammatory drug sulindac is a potent stimulator of SAT1, which facilitates N-acetylation of polyamines and polyamine export via the diamine exporter, DAX. 28, 106 One potential way that polyamines may help PDAC tumors gain immune privilege is via spermine secretion into the tumor microenvironment either by PDAC or other adjacent cell types in the tumor microenvironment. As such, a PTI may be especially effective in PDAC as it would presumably block uptake of spermine into the infiltrating immune cells and give rise to an enhanced immune response against the tumor.
A recent review suggests the presence of numerous polyamine transport systems in mammalian cells and only recently have some of the transport genes been identified. 43 As such, this is a new area for discovery, with diverse applications in oncology and other proliferative diseases. 8, 27, 107 A combination therapy of the polyamine biosynthesis inhibitor (DFMO) plus a PTI should be very effective in disrupting both polyamine metabolism and exchange. Since polyamines are known to inhibit immune cell function, a direct relationship is anticipated between exogenous polyamine concentration and expected immune cell response. 85, 86, 108, 109 In support of this idea, we demonstrated in L3.6pl human PDAC cells that a significant reservoir of intracellular spermidine exists and that the DFMO 1 PTI combination therapy needed to deplete >80% of intracellular spermidine to affect PDAC cell growth. 7 In addition, we identified a murine pancreatic cancer cell line (PanO2) with high polyamine transport activity. 54 These PanO2 cells were readily rescued in vitro from DFMO treatment by exogenous spermidine, which was consistent with their high polyamine import activity. 54 The trimer44NMe PTI 1 (Fig. 1) , which competitively inhibits import of 3 H-labeled spermidine, was shown to work synergistically with DFMO to deplete PDAC cells of intracellular polyamine pools and reduce their growth.
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Conclusions
In closing, we note that PDAC gains many survival advantages via its "addiction" to polyamines. First, the high intracellular spermidine pools provide a resource to potentially biosynthesize and secrete high levels of spermine as an immune suppressant. Second, spermidine can induce autophagy by inhibiting EP-300, 88 which likely helps PDAC survive the consequences of its own high metabolic flux, increased ROS levels and genomic instability. 90 Third, polyamine secretion can provide numerous polyamine substrates to fuel desmoplasia via extracellular TGM2 activity. Indeed, desmoplasia is present in both primary tumors and metastases of PDAC. 110 In summary, numerous reports in the literature describe roles for polyamines in PDAC growth, its microenvironment, desmoplasia and the immune response. Combination therapies, which reduce polyamine levels, have been shown to slow tumor growth and enhance the immune response. 10, 11, 111 Lastly, this area is ripe for drug discovery and future success in designing efficient polyamine-targeting therapies could have broad applications in many human diseases, which rely on polyamines for growth and intercellular communication. 107, 112, 113 
